SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of December 2025. The filing, dated December 8, 2025, serves to incorporate a press release (Exhibit 99.1) by reference into the company's Registration Statements on Form S-8. The registrant is a foreign private issuer based in Mechelen, Belgium.
Key Financial Metrics
The filing text does not provide specific financial data. No values are disclosed for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts solely as a conduit for the attached press release.
Material Changes
The filing does not contain comparative financial data or details regarding material changes versus prior periods. The content is limited to the procedural incorporation of a press release issued on December 8, 2025.
Guidance, Outlook, and Risks
Specific guidance, outlook, management commentary, risks, or contingencies are not detailed in the body of this Form 6-K. The document notes that the press release (Exhibit 99.1) contains a quote from Marie José Kersten, MD, but the text of the quote and the substance of the press release are not included in the provided input.
Investor Verification Checklist
- Verify the actual content of the press release attached as Exhibit 99.1, as the summary relies entirely on that external document.
- Confirm the identity of the registrant as Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" label in the request metadata.
- Review the specific details of the announcement made on December 8, 2025, to understand the material event triggering this filing.
- Check the referenced Form S-8 registration statements for any updated terms related to the press release.